Filter by content type
Filter by year
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
March 6, 2019 - … of the posters are below: Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … of the posters are below: Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 1, 2019 - … : Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … : Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
November 14, 2019 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
Sat, 06/01/2019 - 09:00 - … ASCO Annual Meeting: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in … (NSCLC) … ASCO Annual Meeting: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) …
Mon, 04/01/2019 - 13:00 - … ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 24, 2019 - … inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in … inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of …
AACR 2019 Meeting: Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Updated interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients
Pagination
- Previous page
- Page 2
- Next page